6949 Stock Overview
A biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pell Bio-Med Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$85.40 |
| 52 Week High | NT$178.50 |
| 52 Week Low | NT$70.60 |
| Beta | 0 |
| 11 Month Change | -4.37% |
| 3 Month Change | 5.69% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.09% |
Recent News & Updates
Shareholder Returns
| 6949 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.7% | -0.3% | 2.2% |
| 1Y | n/a | 1.9% | 31.0% |
Return vs Industry: Insufficient data to determine how 6949 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 6949 performed against the TW Market.
Price Volatility
| 6949 volatility | |
|---|---|
| 6949 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 4.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6949 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6949's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 88 | Cheng Long Lin | www.pellbmt.com |
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies.
Pell Bio-Med Technology Co., Ltd. Fundamentals Summary
| 6949 fundamental statistics | |
|---|---|
| Market cap | NT$4.94b |
| Earnings (TTM) | -NT$386.20m |
| Revenue (TTM) | NT$18.41m |
267.7x
P/S Ratio-12.8x
P/E RatioIs 6949 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6949 income statement (TTM) | |
|---|---|
| Revenue | NT$18.41m |
| Cost of Revenue | NT$30.84m |
| Gross Profit | -NT$12.42m |
| Other Expenses | NT$373.78m |
| Earnings | -NT$386.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.69 |
| Gross Margin | -67.47% |
| Net Profit Margin | -2,097.55% |
| Debt/Equity Ratio | 0% |
How did 6949 perform over the long term?
See historical performance and comparison